Cyclacel Confirms Nasdaq Listing for Common & Preferred Stock

TL;DR

**Cyclacel's common and preferred stock remain listed on Nasdaq, ensuring continued trading.**

AI Summary

Cyclacel Pharmaceuticals, Inc. filed an 8-K on January 12, 2024, to report that its Common Stock, with a par value of $0.001 per share, is registered on The Nasdaq Capital Market under the trading symbol CYCC. The filing also notes the company's Preferred Stock, also with a $0.001 par value. This matters to investors because it confirms the continued listing and trading of Cyclacel's shares on a major exchange, providing liquidity and visibility for current and potential shareholders.

Why It Matters

This filing confirms Cyclacel's continued listing on The Nasdaq Capital Market, which is crucial for maintaining investor confidence and ensuring the liquidity of its shares.

Risk Assessment

Risk Level: low — This filing is a routine disclosure confirming existing stock listings and does not introduce new financial risks or operational changes.

Analyst Insight

Investors should view this as a routine compliance filing, confirming the status quo of Cyclacel's stock listings. No immediate action is suggested based solely on this information, but it reinforces the company's presence on a major exchange.

Key Numbers

• $0.001 — Par Value per Share (for both Common Stock and Preferred Stock)

Key Players & Entities

• Cyclacel Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
• The Nasdaq Capital Market (company) — the exchange where Cyclacel's stock is registered
• $0.001 (dollar_amount) — par value per share for both Common and Preferred Stock
• CYCC (company) — trading symbol for Cyclacel's Common Stock

Forward-Looking Statements

• Cyclacel Pharmaceuticals, Inc. will maintain its listing on The Nasdaq Capital Market. (Cyclacel Pharmaceuticals, Inc.) — high confidence, target: 2025-01-12

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share CYCC The Nasdaq Capital Ma
• $0.15 — uarterly cash dividend in the amount of $0.15 per share on the Company's 6% Convertib

Filing Documents

• tm243257d1_8k.htm (8-K) — 26KB
• 0001104659-24-003670.txt ( ) — 238KB
• cycc-20240112.xsd (EX-101.SCH) — 3KB
• cycc-20240112_def.xml (EX-101.DEF) — 26KB
• cycc-20240112_lab.xml (EX-101.LAB) — 36KB
• cycc-20240112_pre.xml (EX-101.PRE) — 25KB
• tm243257d1_8k_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. Declaration of Quarterly Cash Dividend on 6% Convertible Exchangeable Preferred Stock On January 12, 2024, the Board of Directors (the " Board ") of Cyclacel Pharmaceuticals, Inc. (the " Company ") declared a quarterly cash dividend in the amount of $0.15 per share on the Company's 6% Convertible Exchangeable Preferred Stock (" Preferred Stock "). The cash dividend will be payable on February 1, 2024 to the holders of record of the Preferred Stock as of the close of business on January 22, 2024. The Board considered numerous factors in determining whether to declare the quarterly dividend, including the requisite financial analysis and determination of a surplus. While the Board will analyze the advisability of the declaration of dividends in future quarters, there is no assurance that future quarterly dividends will be declared.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CYCLACEL PHARMACEUTICALS, INC. By: /s/ Paul McBarron Name: Paul McBarron Title: Executive Vice President-Finance, Chief Financial Officer and Chief Operating Officer Date: January 12, 2024

View Full Filing

View this 8-K filing on SEC EDGAR